Entrada Therapeutics, Inc.TRDANASDAQ
Loading
Cash & Equivalents Over TimeContracting
Percentile Rank67
3Y CAGR+26.0%
5Y CAGR+18.3%
Studio
Year-over-Year Change

Cash on hand plus short-term liquid investments

3Y CAGR
+26.0%/yr
Annual compound
5Y CAGR
+18.3%/yr
Recent acceleration
Percentile
P67
Within normal range
vs 5Y Ago
2.3x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$90.39M-10.7%
2024$101.21M+49.7%
2023$67.60M+49.7%
2022$45.16M-84.5%
2021$291.06M+645.5%
2020$39.05M+131.8%
2019$16.84M-